Vaxart (VXRT) to Release Earnings on Wednesday

Vaxart (NASDAQ:VXRT) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Vaxart (NASDAQ:VXRT) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). Vaxart had a negative return on equity of 114.19% and a negative net margin of 543.21%. The company had revenue of $6.40 million during the quarter, compared to analysts’ expectations of $65.70 million. During the same period last year, the firm posted ($0.16) earnings per share. On average, analysts expect Vaxart to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Vaxart Stock Performance

NASDAQ VXRT opened at $0.72 on Friday. The company has a market capitalization of $127.75 million, a PE ratio of -1.57 and a beta of 0.70. Vaxart has a 52-week low of $0.52 and a 52-week high of $1.54. The company has a 50-day simple moving average of $0.83 and a 200 day simple moving average of $0.77.

Analyst Ratings Changes

Separately, Oppenheimer initiated coverage on Vaxart in a research note on Thursday, August 15th. They issued an “outperform” rating and a $4.00 price objective on the stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.